Welcome to our dedicated page for Belite Bio SEC filings (Ticker: BLTE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Belite Bio, Inc (NASDAQ: BLTE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer, including Form 6‑K current reports and shelf registration materials. These documents show how Belite Bio communicates key developments around its clinical programs, financings, and regulatory interactions for its lead candidate, Tinlarebant.
Belite Bio uses Form 6‑K to furnish press releases on topics such as quarterly financial results and corporate updates, completion of enrollment in pivotal trials like the global Phase 3 PHOENIX study in geographic atrophy, and progress in the Phase 3 DRAGON program in Stargardt disease type 1 (STGD1). Other 6‑K filings describe securities purchase agreements for registered direct offerings and private placements, including details on American Depositary Shares, warrants, and registration rights agreements.
Through its filings, the company also references its shelf registration statement on Form F‑3, which supports offerings of American Depositary Shares used to fund clinical development, regulatory milestones, and commercialization preparation. While Belite Bio’s filings do not include U.S. domestic forms such as 10‑K or 10‑Q, they serve a similar role in updating investors on business progress, clinical trial status, and capital structure.
On Stock Titan, users can review Belite Bio’s SEC submissions in one place and use AI-powered summaries to interpret complex financing terms, understand the context of clinical and regulatory announcements, and see how new capital raises relate to ongoing trials in STGD1 and geographic atrophy. Filings related to equity offerings, warrants, and registration rights can help readers follow potential dilution, capital availability, and the company’s strategy for funding late-stage drug development.
BELITE BIO, INC Chief Medical Officer Hendrik Peter Scholl filed an initial ownership report showing indirect equity positions held through Bioptima Ltd. These include stock options over 100,000, 75,000 and 40,000 ordinary shares with exercise prices of 48.6800, 54.8800 and 158.3600, expiring between 2034 and 2036, plus 35,000 ordinary shares. Footnotes describe time-based vesting, with portions of these options vesting around September 1, 2025 and January 9 in 2027, 2028 and 2029, subject to continued service.
Belite Bio, Inc. filed an initial insider ownership report for Chief Scientific Officer Nathan L. Mata, detailing his existing equity holdings. The filing shows stock options to purchase 123,066 ordinary shares at an exercise price of $6.0000 per share, expiring on April 17, 2032, which had fully vested before March 18, 2026. It also lists options on 100,000 ordinary shares at $14.4500 per share expiring on July 16, 2033, and 100,000 ordinary shares at $48.4600 per share expiring on August 28, 2034, both subject to monthly vesting schedules tied to continued service. In addition, he directly holds 16,666 American depositary shares and 16,666 ordinary shares, with each ADS representing one ordinary share.
Belite Bio, Inc. director and Chief Financial Officer Chuang Hao-Yuan filed a Form 3 disclosing his existing equity holdings in the company. The filing lists several stock options to acquire ordinary shares, including options over 144,868 shares at an exercise price of $0.4386 per share expiring on December 22, 2030, and 26,112 shares at $6.00 per share expiring on April 17, 2032.
Additional options cover 120,834 ordinary shares at $14.45, 250,000 shares at $48.46, 200,000 shares at $54.88, 40,000 shares at $77.40, 80,000 shares at $93.02, and 150,000 shares at $158.36, each with expirations between 2033 and 2036. The filing also reports direct holdings of 100,000 American depositary shares and 195,264 ordinary shares, with each ADS representing one ordinary share.
BELITE BIO, INC director Chen Xiao-Hui has filed an initial ownership report showing a modest personal stake in the company. The Form 3 indicates beneficial ownership of 400 American depositary shares as of March 18, 2026. Each American depositary share represents one ordinary share of Belite Bio, giving the director economic exposure to 400 ordinary shares. This filing does not reflect a new purchase or sale, but simply records existing holdings as the director becomes subject to insider reporting rules.
BELITE BIO director John Michael Longo reported his initial beneficial ownership on a Form 3, showing two stock option awards over ordinary shares. One option allows him to buy 50,000 shares at $6.0000 per share, expiring on April 17, 2032, vesting monthly from April 28, 2022 over three years. A second option covers 60,000 shares at an exercise price of $58.8800, expiring on April 14, 2035, vesting in 36 equal monthly installments starting after April 15, 2025, subject to continued service.
BELITE BIO, INC director Lu Ita filed an initial Form 3 showing existing stock option holdings. The filing reports a stock option over 50,000 ordinary shares with a $14.45 exercise price, expiring on July 16, 2033. This option vests 22,500 shares on July 17, 2023, with the remaining 27,500 shares vesting in 22 equal monthly installments following June 28, 2023, subject to continued service.
The filing also reports a second stock option over 60,000 ordinary shares with a $58.88 exercise price, expiring on April 14, 2035. This option vests in 36 equal monthly installments for each full month of services completed following April 15, 2025, also subject to continued service. The document records holdings only and does not show any new purchases or sales.
Belite Bio director Gary Clark Biddle filed an initial ownership report showing stock option holdings in the company. He holds options covering 50,000 ordinary shares at an exercise price of $6.00 per share, expiring on April 17, 2032. This option vests over three years: 20,000 shares vest in 12 equal monthly installments after April 28, 2022, and the remaining 30,000 vest in 24 monthly installments after the first anniversary of that date, all subject to continued service. He also holds options over 60,000 ordinary shares at an exercise price of $58.88 per share, expiring on April 14, 2035, which vest in 36 equal monthly installments after April 15, 2025, subject to continued service. The filing lists these option positions and vesting terms rather than reporting any share purchases or sales.
Belite Bio, Inc. director and CEO Lin Yu-Hsin has reported initial equity holdings, including stock options and share positions. The filing lists multiple stock options over ordinary shares with exercise prices from $0.4386 to $158.3600, expiring between 2030 and 2036. Several options are already fully vested, while others vest monthly through August 2028 and in annual tranches on January 9, 2027, January 9, 2028, and January 9, 2029. Lin also holds American depositary shares and ordinary shares directly. This Form 3 records existing positions; it does not show new buying or selling activity.
Belite Bio director Chen Wan-Shan filed an initial ownership report showing direct holdings in the company. The filing lists 10,196 American depositary shares and 23,463 ordinary shares held directly. A footnote explains that each American depositary share represents one ordinary share of Belite Bio.
Belite Bio reported preliminary, unaudited fourth quarter and full-year 2025 results alongside a corporate update. The year was highlighted by positive topline data from the pivotal Phase 3 DRAGON trial of tinlarebant in Stargardt disease and completion of a $402 million public offering, strengthening the balance sheet.
As of December 31, 2025, cash and cash equivalents were $352.9 million and investments in U.S. treasuries were $419.7 million. Full-year 2025 GAAP research and development expenses were $45.4 million and selling, general and administrative expenses were $38.8 million, driving a GAAP net loss of $77.6 million, or $2.31 per share. On a non-GAAP basis, excluding share-based compensation, full-year net loss was $38.7 million. Management plans to submit an NDA for tinlarebant to the FDA in the second quarter of 2026.